How Tigecycline's Excipients Affect Absorption
Tigecycline, a glycylcycline antibiotic, is administered intravenously, bypassing oral absorption issues common with excipients like lactose that cause GI intolerance in other tetracyclines. Its formulation includes sodium metabisulfite as an antioxidant excipient, which stabilizes the lyophilized powder but has minimal direct impact on absorption since it's diluted in saline or dextrose for infusion. No significant excipient-related delays in onset occur; peak plasma levels reach within 30-60 minutes post-infusion.[1]
Excipients' Role in Tigecycline Distribution
Excipients such as mannitol (bulking agent) and sodium hydroxide (pH adjuster) in Tygacil's formulation aid reconstitution without altering tigecycline's high tissue penetration. Tigecycline distributes widely into skin, lung, and intra-abdominal tissues due to its large volume of distribution (7-10 L/kg), independent of excipients. Sodium metabisulfite may cause rare hypersensitivity reactions affecting distribution in sensitive patients, but it does not bind tigecycline or change protein binding (71-89%).[1][2]
Impact on Metabolism
Tigecycline undergoes minimal hepatic metabolism, primarily via reduction to non-active metabolites, with excipients playing no direct role. The formulation's excipients—hydroxyethyl cellulose, hydrochloric acid, and others—do not induce CYP450 enzymes or compete for metabolic pathways. Phase I trials confirm stability in plasma without excipient-mediated degradation, preserving tigecycline's ~20% metabolic clearance.[2]
Effects on Excretion and Elimination Half-Life
Excipients do not significantly influence tigecycline's excretion, which is mostly biliary/fecal (59%) with 33% renal. Half-life remains 42 hours regardless of formulation components. Mannitol, a non-absorbed osmotic diuretic excipient, clears renally without interacting with tigecycline's glucuronidation or P-gp efflux. In vitro stability data show no excipient-induced precipitation in urine or bile, supporting consistent pharmacokinetics (CL 0.2 L/h/kg).[1][2]
Clinical Implications for Therapy Optimization
Understanding minimal excipient impact allows dose adjustments based on renal/hepatic function rather than formulation changes: 100 mg IV load, then 50 mg q12h. In obese patients, higher exposures occur without excipient adjustments. Rare sulfite allergies from metabisulfite prompt monitoring, but no routine excipient swaps exist. This supports fixed dosing to minimize resistance risks and improve outcomes in complicated infections.[2][3]
Reported Excipient-Related Adverse Events
Hypersensitivity to sodium metabisulfite (0.1-1% incidence) can mimic infusion reactions, potentially confusing with tigecycline's nausea (26%). No excipient-driven pharmacokinetic changes reported in post-marketing data. Patients with sulfite sensitivity may need alternatives like alternatives like eravacycline.[3]
Sources
[1]: Tygacil Prescribing Information (Pfizer)
[2]: Tigecycline FDA Label and Pharmacokinetics
[3]: DrugPatentWatch.com - Tygacil Formulation Patents